A pooled analysis of efficacy with trabectedin as 2nd/3rd line single agent in Relapsed Ovarian Cancer (ROC) patients (pts) with a Platinum-Free Interval (PFI) of 6-12 months

被引：0
|
作者：
Kurzeder, C. [1 ]
Del Campo, J. M. [2 ]
Sessa, C. [3 ]
Zintl, P. [4 ]
De la Riba, M., I [4 ]
Nieto, A. [4 ]
Kreienberg, R. [1 ]
机构：
[1] Unifrauenklin, Ulm, Germany
[2] Valle Hebron Hosp, Barcelona, Spain
[3] Osped Reg Bellinzona & Valli, IOSI Oncol Inst So Switzerland, Bellinzona, Switzerland
[4] PharmaMar, Madrid, Spain
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190 / 191
页数：2
相关论文
共 8 条
  • [1] Trabectedin (Tr) as single agent in relapsed ovarian cancer (ROC) patients (pts) with a platinum-free interval (PFI) of 6 to 12 months
    del Campo, J.
    Ciuleanu, T.
    Sessa, C.
    Westermann, A. M.
    Roszak, A.
    Chan, S.
    Hogberg, T.
    Zintl, P.
    Park, Y. C.
    Krasner, C. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial
    Poveda, A.
    Vergote, I.
    Tjulandin, S.
    Kong, B.
    Roy, M.
    Chan, S.
    Filipczyk-Cisarz, E.
    Hagberg, H.
    Kaye, S. B.
    Colombo, N.
    Lebedinsky, C.
    Parekh, T.
    Gomez, J.
    Park, Y. C.
    Alfaro, V.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 39 - 48
  • [3] Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr plus PLD) versus PLD alone: Results from a PPS cohort of a phase III study
    Poveda, A.
    Tjulandin, S.
    Kong, B.
    Roy, M.
    Chan, S.
    Filipczyk-Cisarz, E.
    Hagberg, H.
    Lebedinsky, C.
    Parekh, T. V.
    Monk, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Yondelis®) plus pegylated liposomal doxorubicin (Caelyx®[PLD]) combination versus PLD alone: Results from a PPS cohort of the OVA-301 phase III study
    Lehmann-Willenbrock, E.
    Runnebaum, I
    Nieto, A.
    Poveda, A.
    Monk, B. J.
    De la Riba, M., I
    Meerpohl, H-G
    ONKOLOGIE, 2010, 33 : 190 - 190
  • [5] Phase 1/2 study of galinpepimut-S plus pembrolizumab combination in patients with WT1+platinum-resistant ovarian cancer in 2nd/3rd line of therapy
    OCearbhaill, Roisin
    Holmes, Jarrod
    Bastos, Bruno
    Fu, Siqing
    Muenzen, Reid
    Cohen, Julia
    Cicic, Dragan
    Ali, Sami
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A199 - A200
  • [6] Erlotinib as single agent in 2nd and 3rd line treatment in patients with metastatic colorectal cancer. Results of a two-cohort multicenter phase II trial
    Niederle, N.
    Freier, P.
    Porschen, R.
    Arnold, D.
    Lordick, F.
    Hoehler, T.
    Kubicka, S.
    Kettnera, E.
    Keilholz, U.
    Schmoll, H.-J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 184 - 184
  • [7] The MITO8 phase 3 international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum based chemotherapy. A collaboration of MITO, Mango, AGO Study Group, BGOG, ENGOT, and GCIG
    Piccirillo, M. C.
    Scambia, G.
    Bologna, A.
    Vergote, I.
    Baumann, K.
    Raspagliesi, F.
    Murgia, V.
    Pisano, C.
    Salutari, V.
    Sorio, R.
    Ferrandina, G.
    Sacco, C.
    Cormio, G.
    Breda, E.
    Cinieri, S.
    Cecere, S. C.
    Daniele, G.
    Gallo, C.
    Perrone, F.
    Pignata, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG.
    Pignata, Sandro
    Scambia, Giovanni
    Raspagliesi, Francesco
    Murgia, Viviana
    Pisano, Carmela
    Salutari, Vanda
    Bologna, Alessandra
    Sorio, Roberto
    Ferrandina, Gabriella
    Sacco, Cosimo
    Vergote, Ignace
    Cormio, Gennaro
    Breda, Enrico
    Cinieri, Saverio
    Cecere, Sabrina Chiara
    Wagner, Uwe A. G.
    Daniele, Gennaro
    Gallo, Ciro
    Perrone, Francesco
    Piccirillo, Maria Carmela
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
1